

## Boron Neutron Capture Therapy for Breast Cancer



Zafer Akan<sup>1\*</sup>

Boron neutron capture therapy (BNCT) was introduced in 1960's, but showed little development, as the thermal and epithermal neutron sources were not economical. Nuclear reactors, and recently cyclotrons are being used as neutron sources, thus enabling its widespread utilization (1).

Gamma rays are utilized for the irradiation of tumor tissues, and fractional doses up to 50-60 Gray required for tumor ablation in conventional radiation therapy. Such high doses naturally irradiate healthy tissues, and thus result in healthy tissue injury.

BNCT was proposed to abolish the side effects of conventional radiation therapy, and basically is a reaction that consists of, targeted of <sup>10</sup>B to the tumor tissue and irradiation with <sup>1</sup>n neutron, and subsequent fission into toxic <sup>7</sup>Li and <sup>4</sup>alpha particles within the tumor tissue.

(<sup>10</sup>B+<sup>1</sup>n →<sup>7</sup>Li+<sup>4</sup>He +2.31MeV (93.7%) or <sup>10</sup>B+<sup>1</sup>n →<sup>7</sup>Li+<sup>4</sup>He +2.79MeV (6.3%)).

The resulting lithium ions and particles are high linear energy transfer (LET) particles, which produce considerable biological effects. Their short range in tissue (5-9 mm) restricts radiation damage to those cells in which boron atoms are located at the time of neutron irradiation (2).

Boron phenyl alanine (BPA), sodium boronocaptate (BSH), and the molecule our team works on, namely Borono-Deoxy-D-Glucose (BDG) are being used for the targeting of boron into the tumor tissue.

BNCT was primarily intended to be utilized for the treatment of neck and head cancers due to the technical difficulties and economically burden. Technical improvements in BNCT application has led to consideration of this technique in soft tissue tumors such as breast cancer (3).

Breast cancer is the most common cancer among females, and particularly recurrent breast cancers (RBC) are threatening for women. Radiation therapy is commonly the preferred method of treatment, but has some side effects and insufficient effects against RBC. Recently, BNCT comes to the fore as an alternative approach to therapy.

Successful *in vitro* and simulation studies has led scientists to anticipate successful clinical results in the near future (4,5).

Maximization of BNCT's therapeutic potential requires the combination of a suitable thermal/epithermal neutron flux in association with a selective intake of <sup>10</sup>B-boron nuclei in the target tissue.

With new boron carrier designs and neutron sources, BNCT can fill an important niche for those malignancies, whether primary or recurrent, for which there is currently no effective therapy.

Zafer Akan obtained his PhD degree from School of Medicine, Marmara University, Turkey in 2008. He is working at School of Medicine, Celal Bayar University, Turkey as Assistant Professor. He has focused on the areas such as environmental pollutions, electromagnetic fields, cancer molecular biology, and boron neutron capture therapy. He is recognized as the Owner and Chief Editor of International Journal of Medical Science and Discovery.



### References

1. Barth RF. Boron neutron capture therapy at the crossroads: Challenges and Opportunities. *Appl Radiat Isot* 2009; 67: S3-S6
2. Yanagie H, Kumada H, Sakurai Y, Nakamura T, Furuya Y, Sugiyama H, et al. Dosimetric evaluation of neutron capture therapy for local advanced breast cancer. *Appl Radiat Isot* 2009; 67(7-8 Suppl): S63-6. doi: 10.1016/j.apradiso.2009.03.110
3. Akan Z, Demiroglu H, Avcibasi U, Oto G, Ozdemir H, Deniz S, et al. Complexion of Boric Acid with 2-Deoxy-D-glucose (DG) as a novel boron carrier for BNCT. *Med Sci Discovery* 2014; 1(3): 65-71
4. Menichetti L, Gaetano L, Zampolli A, Del Turco S, Ferrari C, Bortolussi S, et al. In vitro neutron irradiation of glioma and endothelial cultured cells. *Appl Radiat Isot*. 2009; 67(7-8 Suppl):S336-40. doi: 10.1016/j.apradiso.2009.03.058.
5. Horiguchi H, Nakamura T, Kumada H, Yanagie H, Suzuki M, Sagawa H. Investigation of irradiation conditions for recurrent breast cancer in JRR-4. *Appl Radiat Isot* 2011; 69(12): 1882-4. doi: 10.1016/j.apradiso.2011.03.036.

Copyright © 2015 The Author(s); This is an open-access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received 7 November 2014, Accepted 14 December 2014, Available online 7 February 2015

<sup>1</sup>Celal Bayar University Faculty of Medicine, Department of Biophysics, Manisa, Turkey.

\*Corresponding author: Zafer Akan; Tell: 0090 2362331920, Email: zafer.akan@cbu.edu.tr

